BOULDER, Colo.--(BUSINESS WIRE)--

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017. AACR will take place April 1-5, 2017 in Washington, DC. The data being presented provide greater insight into the mechanism of action and function of rucaparib in multiple disease and therapy settings.

“These data demonstrate Clovis Oncology’s commitment to fully understanding rucaparib’s mechanism of action as well as the therapeutic settings in which it may offer the most benefit to patients,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.

Rucaparib is the Company’s oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3. The FDA approved rucaparib (Rubraca^®) tablets in December 2016 for the monotherapy treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutations treated with two or more chemotherapies. Rucaparib is also being developed for other oncology indications in which patients may possess mutant BRCA tumors and other DNA repair deficiencies beyond BRCA – commonly referred to as homologous recombination deficiencies, or HRD.

Data from preclinical rucaparib studies are the subject of four poster presentations at the AACR meeting:

Abstract 2475 – In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib

• Presenter: Andrew J. Simmons, Ph.D., Translational Medicine, Clovis Oncology
• Date/Time: Monday, April 3, 1:00-5:00 p.m. ET
• Location: Halls A-C

Abstract 2476 – Preclinical assessment of the PARP inhibitor rucaparib in homologous recombination deficient prostate cancer models

• Presenter: Minh Nguyen, Translational Medicine, Clovis Oncology
• Date/Time: Monday, April 3, 1:00-5:00 p.m. ET
• Location: Halls A-C

Abstract 3650 – Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

• Presenter: Liliane Robillard, Translational Medicine, Clovis Oncology
• Date/Time: Tuesday, April 4, 8:00 a.m.–12:00 p.m. ET
• Location: Halls A-C

Abstract 4676 – DNA repair protein expression and response of homologous recombination deficient ovarian cancer to the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in the ARIEL2 Part 1 study

• Presenter: Andrea E. Wahner Hendrickson, M.D., Assistant Professor of Oncology, Medical Oncology, Mayo Clinic, Rochester, Minnesota
• Date/Time: Tuesday, April 4, 1:00-5:00 p.m. ET
• Location: Halls A-C

Each presentation will be available online at http://clovisoncology.com/pipeline/scientific-presentations/ as of the time of presentation at the meeting.

About Rucaparib

Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. The MAA submission in Europe for an ovarian cancer treatment indication was submitted and accepted during the fourth quarter of 2016. Additionally, rucaparib is being developed as maintenance therapy for ovarian cancer in the ARIEL3 trial for patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, as well as biomarker negative patients. Data from ARIEL3 are expected in mid-2017, which, pending positive data, is expected to be followed by the submission of a supplemental NDA for a second line or later maintenance indication. Rucaparib is also being developed in patients with mutant BRCA tumors and other DNA repair deficiencies beyond BRCA – commonly referred to as homologous recombination deficiencies, or HRD. Studies open for enrollment or under consideration include prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers. Clovis holds worldwide rights for rucaparib.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Please visit clovisoncology.com for more information.

To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in whether future study results will be consistent with study findings to-date, the clinical development programs for our drug candidates and expectations with respect to regulatory submissions and approvals. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006238/en/